Crescent Biopharma
CBIO
41 hedge funds and large institutions have $135M invested in Crescent Biopharma in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
37% more funds holding
Funds holding: 30 → 41 (+11)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
16.66% less ownership
Funds ownership: 16.66% → 0% (-17%)
22% less capital invested
Capital invested by funds: $174M → $135M (-$39M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.73M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.35M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.09M |
| 4 |
BlackRock
New York
|
+$1.37M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$10.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$4.22M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$3.48M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.65M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.4M |
CBIO Hedge Fund Activity: Q3 2025 in Review
41 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2025, worth a combined $135M — down 22% from $174M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CBIO positions and 4 closed out — a net gain of 11 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $8.73M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $10.4M sold.
- 41 institutional investors held Crescent Biopharma (CBIO) as of Q3 2025, up from 30 in Q2 2025.
- Funds reported $135M of Crescent Biopharma stock for Q3 2025, down 22% quarter-over-quarter.
- 15 funds opened new Crescent Biopharma positions in Q3 2025 and 4 closed out, a net change of +11 holders.
- The largest Crescent Biopharma buyer in Q3 2025 was Vanguard Group, an estimated $8.73M added.
- The largest Crescent Biopharma seller in Q3 2025 was Paradigm Biocapital Advisors, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2025.